Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but investors' concerns about safety seem to be weighing on its share price.
Scientists have developed a new transgene control system that shows early promise for treating rare brain disorder Rett syndrome.
Neurogene (NGNE) announced a peer-reviewed publication on its EXACT transgene regulation technology. The preclinical ...
Biomed Industries, Inc. Announces Phase 2/3 Results of NA-921, with Strong Efficacy and Superior Safety for Rett Syndrome Treatment The Phase 2/3 results of NA-921 show strong potential as an ...
11d
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and ...
The company has secured Regenerative Medicine Advanced Therapy (RMAT) designation for Rett syndrome, which could potentially expedite the approval process. An upcoming Type B meeting under the RMAT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback